NCT03225716View on ClinicalTrials.gov

A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 20, 2017

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Waldenstrom's Macroglobulinemia
Interventions
DRUG

Ulocuplumab

Ulocuplumab is a type of protein called an antibody that attacks CXCR4

DRUG

Ibrutinib

Ibrutinib small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity

Trial Locations (1)

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT03225716 - A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia | Biotech Hunter | Biotech Hunter